These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 9679400)

  • 1. [Prognostic value of the initial response of serum estradiol levels to stimulation with GnRH analogues in in vitro fertilization].
    Cabra R; Muñiz M; Jaroslav Stern J; Verez JR; Gutiérrez Najar AJ
    Ginecol Obstet Mex; 1998 Jun; 66():242-7. PubMed ID: 9679400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.
    Cabrera RA; Stadtmauer L; Mayer JF; Gibbons WE; Oehninger S
    Fertil Steril; 2005 Jan; 83(1):42-8. PubMed ID: 15652885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic value assessment of the early response of blood estradiol, FSH, and LH using leuprolide acetate during ovarian hyperstimulation in assisted reproduction].
    Sondón García Z; Alvarado A; Peraza Briones C; González Sánchez R; Jiménez Perea L
    Ginecol Obstet Mex; 2001 Feb; 69():65-71. PubMed ID: 11339176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG; Bourgain C; Kolibianakis E; Tournaye H; Devroey P
    Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
    Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P
    Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study.
    Pirard C; Donnez J; Loumaye E
    Hum Reprod; 2006 Jul; 21(7):1894-900. PubMed ID: 16556673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of the early serum estradiol response to leuprolide acetate in in vitro fertilization.
    Padilla SL; Bayati J; Garcia JE
    Fertil Steril; 1990 Feb; 53(2):288-94. PubMed ID: 2105245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and endocrine effects of ovulation induction with FSH and hCG supplementation in low responders in the midfollicular phase. A pilot study.
    Ferrari B; Barusi L; Coppola F
    J Reprod Med; 2002 Feb; 47(2):137-43. PubMed ID: 11883353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial.
    Fatemi HM; Kolibianakis EM; Camus M; Tournaye H; Donoso P; Papanikolaou E; Devroey P
    Hum Reprod; 2006 Oct; 21(10):2628-32. PubMed ID: 16857887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of estradiol supplementation during the luteal phase improves the pregnancy rate in women undergoing in vitro fertilization-embryo transfer cycles.
    Lukaszuk K; Liss J; Lukaszuk M; Maj B
    Fertil Steril; 2005 May; 83(5):1372-6. PubMed ID: 15866571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates.
    Lahoud R; Al-Jefout M; Tyler J; Ryan J; Driscoll G
    Hum Reprod; 2006 Oct; 21(10):2645-9. PubMed ID: 16785261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition.
    Hale GE; Hughes CL; Burger HG; Robertson DM; Fraser IS
    Menopause; 2009; 16(1):50-9. PubMed ID: 18978637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human granulosa cells in vitro: influence of GnRH/GnRH-agonist on steroidogenesis and on IVF outcome.
    Stevenson AF
    Indian J Exp Biol; 1999 Dec; 37(12):1167-70. PubMed ID: 10865881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteal estrogen supplementation in pregnancies associated with low serum estradiol concentrations.
    Kaider AS; Coulam CB
    Early Pregnancy (Cherry Hill); 2000 Jul; 4(3):191-9. PubMed ID: 11727011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.